Kiniksa Pharmaceuticals Reports Third-Quarter Revenue of $286M

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa reported third-quarter 2026 revenue of $286.0 million and net income of $47.3 million, compared with revenue of $180.9 million and net income of $18.4 million a year earlier. The company raised its 2026 ARCALYST net product revenue outlook to $1.045 billion—$1.050 billion. Kiniksa also repo…

Kiniksa Pharmaceuticals Q3 ARCALYST revenue jumps 58%; raises guidance Overview US biopharma firm's